The Protection of Naturally Acquired Antibodies Against Subsequent SARS-CoV-2 Infection: A Systematic Review and Meta-Analysis

References

• Xiang L, Tang M, Yin Z, et al. The COVID-19 pandemic and economic growth: theory and simulation. Front Public Health. 2021 Sep;9(1355.
   Google Scholar
• World Health Organization (WHO). Coronavirus (COVID-19) Dashboard [cited Feb 15 2022]. Available from: https://covid19.who.int/.
   Google Scholar
• Staines HM, Kirwan DE, Clark DJ, et al. IgG seroconversion and pathophysiology in severe acute respiratory syndrome coronavirus 2 infection. Emerg Infect Dis. 2021 Jan;27(1.
   PubMed Web of Science ®Google Scholar
• Wajnberg A, Amanat F, Firpo A, et al. Robust neutralizing antibodies to SARS-CoV-2 infection persist for months. Science. 2020 Dec;370(6521):1227-1230.
   PubMed Web of Science ®Google Scholar
• Dan JM, Mateus J, Kato Y, et al. Immunological memory to SARS-CoV-2 assessed for up to 8 months after infection. Science. 2021 Feb 5;371(6529):eabf4063.
   PubMed Web of Science ®Google Scholar
• Gallais F, Gantner P, Bruel T, et al. Anti-SARS-CoV-2 Antibodies Persist for up to 13 Months and Reduce Risk of Reinfection. medRxiv. 2021.
   Google Scholar
• Bao L, Deng W, Gao H, et al. Lack of Reinfection in Rhesus Macaques Infected with SARS-CoV-2. bioRxiv. 2020.
   Google Scholar
• Om E, Byrne P, Walsh KA, et al. Immune response following infection with SARS-CoV-2 and other coronaviruses: A rapid review. Rev Med Virol. 2021 Mar;31(2):e2162.
   PubMed Web of Science ®Google Scholar
• Edridge AWD, Kaczorowska J, Hoste ACR, et al. Seasonal coronavirus protective immunity is short-lasting. Nat Med. 2020 Nov;26(11):1691–1693.
   PubMed Web of Science ®Google Scholar
• Our World In Data. Coronavirus (COVID-19) Vaccinations [cited Feb 16 2022]. Available from: https://ourworldindata.org/covid-vaccinations.
   Google Scholar
• Babiker A, Marvil CE, Waggoner JJ, et al. The importance and challenges of identifying SARS-CoV-2 reinfections. J Clin Microbiol. 2021 Mar 19;59(4):e02769–20.
   PubMed Web of Science ®Google Scholar
• Altmann DM, Douek DC, Boyton RJ. What policy makers need to know about COVID-19 protective immunity. The Lancet. 2020 May;395(10236):1527–1529.
   PubMed Web of Science ®Google Scholar
• Overbaugh J. Understanding protection from SARS-CoV-2 by studying reinfection. Nat Med 2020 Nov;26(11):1680–1681.
   PubMed Web of Science ®Google Scholar
• Khoshkam Z, Aftabi Y, Stenvinkel P, et al. Recovery scenario and immunity in COVID-19 disease: A new strategy to predict the potential of reinfection. J Adv Res. 2021;31:49–60.
   PubMed Web of Science ®Google Scholar
• Krishna E, Pathak VK, Prasad R, et al. COVID-19 reinfection: Linked Possibilities and future outlook. J Family Med Prim Care. 2020 Nov;9(11):5484–5449.
   PubMedGoogle Scholar
• Murchu EO, Byrne P, Carty PG, et al. Quantifying the risk of SARS-CoV-2 reinfection over time. Rev Med Virol. 2021 May: e2260.
   PubMed Web of Science ®Google Scholar
• Chivese T, Matizanadzo JT, Musa OAH, et al. The prevalence of adaptive immunity to COVID-19 and reinfection after recovery – a comprehensive systematic review and meta-analysis. medRxiv. 2021.
   Google Scholar
• Ruiz-Galiana J, Ramos PDL, García-Botella A, et al. Persistence and viability of SARS-CoV-2 in primary infection and reinfections. Rev Esp Quimioter. 2021.
   Web of Science ®Google Scholar
• Farrukh L, Mumtaz A, Sana MK. How strong is the evidence that it is possible to get SARS-CoV-2 twice? A systematic review. Rev Med Virol. 2021.
   PubMed Web of Science ®Google Scholar
• Sciscent BY, Eisele CD, Ho L, et al. COVID-19 reinfection: the role of natural immunity, vaccines, and variants. J Community Hosp Intern Med Perspect. 2021.
   PubMed Web of Science ®Google Scholar
• Perry J, Osman S, Wright J, et al. Does a humoral correlate of protection exist for SARS-CoV-2? A systematic review. medRxiv. 2022.
   Google Scholar
• PROSPERO [cited Nov 10 2021]. Available from: https://www.crd.york.ac.uk/PROSPERO/#recordDetails.
   Google Scholar
• Guido S, Theodore L, FBartos, jbkang. meta: General Package for Meta-Analysis [cited Nov 29 2021]. Available from: https://github.com/guido-s/meta/.
   Google Scholar
• Krutikov M, Palmer T, Tut G, et al. Incidence of SARS-CoV-2 infection according to baseline antibody status in staff and residents of 100 long-term care facilities (VIVALDI): a prospective cohort study. Lancet Healthy Longev. 2021;2(6):e362–e370.
   PubMedGoogle Scholar
• Maier HE, Kuan G, Saborio S, et al. Clinical spectrum of SARS-CoV-2 infection and protection from symptomatic re-infection. Clin Infect Dis. 2021 Aug:ciab717.
   Web of Science ®Google Scholar
• Goldberg Y, Mandel M, Bar-On YM, et al. Protection and waning of natural and hybrid COVID-19 immunity. medRxiv. 2021.
   Google Scholar
• Manica M, Pancheri S, Poletti P, et al. Risk of symptomatic infection during a second coronavirus disease 2019 wave in severe acute respiratory syndrome coronavirus 2–seropositive individuals. Clin Infect Dis. 2021:ciab556.
   Google Scholar
• Shields A, Faustini SE, Perez-Toledo M, et al. SARS-CoV-2 seroprevalence and asymptomatic viral carriage in healthcare workers: a cross-sectional study. Thorax. 2020;75(12):1089–1094.
   PubMed Web of Science ®Google Scholar
• Houlihan CF, Vora N, Byrne T, et al. SARS-CoV-2 virus and antibodies in front-line Health Care Workers in an acute hospital in London: preliminary results from a longitudinal study. medRxiv. 2020.
   Google Scholar
• Eyre DW, Lumley SF, O'Donnell D, et al. Differential occupational risks to healthcare workers from SARS-CoV-2 observed during a prospective observational study. Elife. 2020 Aug;9:e60675.
   PubMed Web of Science ®Google Scholar
• Hellewell J, Russell TW, Investigators S, et al. Estimating the effectiveness of routine asymptomatic PCR testing at different frequencies for the detection of SARS-CoV-2 infections. BMC Med. 2021 Apr;19(1):106.
   PubMed Web of Science ®Google Scholar
• Collier DA, Ferreira I, Kotagiri P, et al. Age-related immune response heterogeneity to SARS-CoV-2 vaccine BNT162b2. Nature. 2021 Aug;596(7872):417–422.
   PubMed Web of Science ®Google Scholar
• Chen Q, Zhao H, Yao X, et al. Comparing immunogenicity of the escherichia coli-produced bivalent human papillomavirus vaccine in females of different ages. Vaccine. 2020 Sep;38(39):6096–6102.
   PubMed Web of Science ®Google Scholar
• Laing ED, Epsi NJ, Richard SA, et al. SARS-CoV-2 antibodies remain detectable 12 months after infection and antibody magnitude is associated with age and COVID-19 severity. medRxiv. 2021.
   Google Scholar
• Rydyznski Moderbacher C, Ramirez SI, Dan JM, et al. Antigen-Specific adaptive immunity to SARS-CoV-2 in acute COVID-19 and associations with Age and disease severity. Cell. 2020 Nov;183(4):996–1012.e19.
   PubMed Web of Science ®Google Scholar
• Aw D, Silva AB, Palmer DB. Immunosenescence: emerging challenges for an ageing population. Immunology. 2007 Apr;120(4):435-46.
   PubMed Web of Science ®Google Scholar
• Global Initiative on Sharing All Influenza Data (GISAID). Genomic epidemiology of novel coronavirus - Global subsampling [cited Feb 15 2022]. Available from: https://nextstrain.org/ncov/gisaid/global.
   Google Scholar
• Li Q, Wu J, Nie J, et al. The impact of mutations in SARS-CoV-2 spike on viral infectivity and antigenicity. Cell. 2020 Sep;182(5):1284-1294.e9 e9.
   PubMed Web of Science ®Google Scholar
• Lopez Bernal J, Andrews N, Gower C, et al. Effectiveness of Covid-19 vaccines against the B.1.617.2 (Delta) variant. N Engl J Med 2021 Aug;385(7):585-594.
   PubMed Web of Science ®Google Scholar
• Pulliam JRC, van Schalkwyk C, Govender N, et al. Increased risk of SARS-CoV-2 reinfection associated with emergence of the Omicron variant in South Africa. medRxiv. 2021.
   Google Scholar
• Quarleri J, Galvan V, Delpino MV. Omicron variant of the SARS-CoV-2: a quest to define the consequences of its high mutational load. Geroscience. 2021 Dec: 1–4.
   Web of Science ®Google Scholar
• U.S. Centers for Disease Control and Prevention. Protocol for Investigating Suspected SARS-CoV-2 Reinfection [cited Oct. 27 2020]. Available from: https://www.cdc.gov/coronavirus/2019-ncov/php/reinfection.html.
   Google Scholar
• Stephens DS, McElrath MJ. COVID-19 and the path to immunity. JAMA. 2020.
   Web of Science ®Google Scholar
• Wilkins JT, Hirschhorn LR, Gray EL, et al. Serologic status and SARS-CoV-2 infection over 6 months of follow Up in healthcare workers in Chicago: A cohort study. Infect Control Hosp Epidemiol. 2021 Aug: 1–9.
   PubMed Web of Science ®Google Scholar
• Lumley SF, O'Donnell D, Stoesser NE, et al. Antibody status and incidence of SARS-CoV-2 infection in Health care workers. N Engl J Med. 2021 Feb;384(6):533–540.
   PubMed Web of Science ®Google Scholar
• Abo-Leyah H, Gallant S, Cassidy D, et al. The protective effect of SARS-CoV-2 antibodies in scottish healthcare workers. ERJ Open Res. 2021;7(2):00080–02021.
   PubMedGoogle Scholar
• Jeffery-Smith A, Iyanger N, Williams SV, et al. Antibodies to SARS-CoV-2 protect against re-infection during outbreaks in care homes, September and October 2020. Euro Surveill. 2021 Feb;26(5.
   PubMedGoogle Scholar
• Harvey RA, Rassen JA, Kabelac CA, et al. Association of SARS-CoV-2 seropositive antibody test With risk of future infection. JAMA Intern Med. 2021 May;181(5):672–679.
   PubMed Web of Science ®Google Scholar
• Shields AM, Faustini SE, Kristunas CA, et al. Longitudinal protection following natural SARS-CoV-2 infection and early vaccine responses: insights from a cohort of community based dental health care professionals. medRxiv. 2021.
   Google Scholar
• Leidi A, Koegler F, Dumont R, et al. Risk of reinfection after seroconversion to SARS-CoV-2: A population-based propensity-score matched cohort study. 2021 May:2021.03.19.21253889.
   Google Scholar
• Clarke CL, Prendecki M, Dhutia A, et al. Longevity of SARS-CoV-2 immune responses in haemodialysis patients and protection against reinfection. medRxiv. 2021.
   Google Scholar
• Hall VJ, Foulkes S, Charlett A, et al. SARS-CoV-2 infection rates of antibody-positive compared with antibody-negative health-care workers in england: a large, multicentre, prospective cohort study (SIREN). The Lancet. 2021;397(10283):1459–1469.
   PubMed Web of Science ®Google Scholar
• Letizia AG, Ge Y, Vangeti S, et al. SARS-CoV-2 seropositivity and subsequent infection risk in healthy young adults: a prospective cohort study. Lancet Respir Med. 2021 Jul;9(7):712–720.
   PubMed Web of Science ®Google Scholar
• Abu-Raddad LJ, Chemaitelly H, Coyle P, et al. SARS-CoV-2 antibody-positivity protects against reinfection for at least seven months with 95% efficacy. EClinicalMedicine. 2021 May;35:100861.
   PubMedGoogle Scholar
• Leidi A, Berner A, Dumont R, et al. Occupational risk of SARS-CoV-2 infection and reinfection during the second pandemic surge: a cohort study. Occup Environ Med. 2021 Dec:oemed-2021-107924.
   Web of Science ®Google Scholar
• Havervall S, Ng H, Jernbom Falk A, et al. Robust humoral and cellular immune responses and low risk for reinfection at least 8 months following asymptomatic to mild COVID-19. J Intern Med. 2022 Jan;291(1):72–80.
   PubMed Web of Science ®Google Scholar
• Schuler CFT, Gherasim C, O'Shea K, et al. Mild SARS-CoV-2 illness Is Not associated with reinfections and provides persistent spike, nucleocapsid, and virus-neutralizing antibodies. Microbiol Spectr. 2021 Oct;9(2):e0008721.
   PubMed Web of Science ®Google Scholar
• Kohler P, Güsewell S, Seneghini M, et al. Impact of baseline SARS-CoV-2 antibody status on syndromic surveillance and the risk of subsequent Covid-19 – a prospective multicentre cohort study. medRxiv. 2021.
   Google Scholar
• Muir L, Jaffer A, Rees-Spear C, et al. Neutralizing antibody responses after SARS-CoV-2 infection in End-stage kidney disease and protection against reinfection. Kidney Int Rep. 2021;Jul6(7):1799–1809.
   PubMed Web of Science ®Google Scholar